Evidence map›Paper›PMID 38031268›Full record

ReviewCurrent protein & peptide science2024

Hypoxia A Typical Target in Human Lung Cancer Therapy.

Asmat Ullah, Somia Shehzadi, Najeeb Ullah, Touseef Nawaz, Haroon Iqbal, Tariq Aziz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Asmat UllahClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, 310014, Zhejiang, China.ORCID 0000-0002-6572-1242
Somia ShehzadiUniversity Institute of Medical Laboratory Technology, The University of Lahore, Lahore, 54000, Pakistan.
Najeeb UllahKey Laboratory of Applied Surface and Colloid Chemistry, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710119, PR, China.
Touseef NawazFaculty of Pharmacy, Gomal University, D.I. Khan, 29050, Pakistan.
Haroon IqbalZhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou, Zhejiang, 310022, China.
Tariq AzizSchool of Engineering, Westlake University, Hangzhou, Zhejiang Province, 310024, China.
Westlake University · CNChinese Academy of Sciences · CNGomal University · PKShaanxi Normal University · CNUniversity of Lahore · PKZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC) is the leading cause of cancer-related death globally. Comprehensive knowledge of the cellular and molecular etiology of LC is perilous for the development of active treatment approaches. Hypoxia in cancer is linked with malignancy, and its phenotype is implicated in the hypoxic reaction, which is being studied as a prospective cancer treatment target. The hypervascularization of the tumor is the main feature of human LC, and hypoxia is a major stimulator of neo-angiogenesis. It was seen that low oxygen levels in human LC are a critical aspect of this lethal illness. However, as there is a considerable body of literature espousing the presumed functional relevance of hypoxia in LC, the direct measurement of oxygen concentration in Human LC is yet to be determined. This narrative review aims to show the importance and as a future target for novel research studies that can lead to the perception of LC therapy in hypoxic malignancies.

Indexed as

Lung NeoplasmsAntineoplastic AgentsCell HypoxiaHumansHypoxiaMolecular Targeted TherapyNeovascularization, PathologicOxygenTumor HypoxiaAntineoplastic AgentsOxygenHIF-1αHypoxialung cancerneo-angiogenesis .oxygen measurementspositron emission tomography

Identifiers

PMID38031268
OpenAlexW4389179040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.